Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 5

Results For "Syngene"

66 News Found

OneSource Specialty Pharma appoints Jeffrey Wong as CBO
People | July 08, 2025

OneSource Specialty Pharma appoints Jeffrey Wong as CBO

He has held senior leadership positions at Syngene International, Fujifilm Diosynth Biotechnologies, Thermo Fisher Scientific, Sartorius Stedim Biotech, and other leading organizations


Biocon Q4 FY25 consolidated PAT jumps 153% to Rs. 344 Cr
News | May 14, 2025

Biocon Q4 FY25 consolidated PAT jumps 153% to Rs. 344 Cr

For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.


Biocon Academy conducts 9th Graduation Day
News | March 04, 2025

Biocon Academy conducts 9th Graduation Day

Notably, 36 female students have been placed in Production and Manufacturing roles, reflecting the growing representation of women in core biotech operations


Biocon Foundation marks 20 years of transforming lives
News | February 28, 2025

Biocon Foundation marks 20 years of transforming lives

Biocon Foundation has been steadfast in its mission to empower underserved communities through innovative healthcare solutions, education, and sustainable development initiatives


India’s CRDMO sector growth potential at $22 - $25 Billion by 2035: BCG-IPSO Report
News | February 26, 2025

India’s CRDMO sector growth potential at $22 - $25 Billion by 2035: BCG-IPSO Report

Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain


Biocon posts Q3 FY25 PAT at Rs. 25 Cr
News | January 31, 2025

Biocon posts Q3 FY25 PAT at Rs. 25 Cr

The group reported Q3FY25 operating revenue of Rs 3,821 crore, driven by sustained double-digit growth of 14 per cent in biosimilars


Anthem Biosciences files DRHP for Rs. 3,395 crore IPO
News | January 01, 2025

Anthem Biosciences files DRHP for Rs. 3,395 crore IPO

Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients


Biocon reports Q2 FY25 net loss at Rs. 16 Cr
News | November 04, 2024

Biocon reports Q2 FY25 net loss at Rs. 16 Cr

Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore


Shilpa Biologicals appoints Dr. Sridevi Khambhampaty as CEO
People | September 20, 2024

Shilpa Biologicals appoints Dr. Sridevi Khambhampaty as CEO

She brings an overall Techno Commercial experience of 22+ Years in various Organizations